Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivisor has signed a new sales and marketing agreement with Cura Pharmaceutical for the marketing of Mucotrol in the US.
Subscribe to our email newsletter
The drug Mucotrol is an oral gel wafer that received 510(k) approval as a device from the FDA in late November 2004, as a treatment for mouth sores related to chemotherapy.
Cura will supply and distribute Mucotrol with Medivisor handling the marketing and sales. Under the terms of the new agreement both parties agree to now share in the net profits.
Dino Luzzi, CEO of Medivisor, said: “We are pleased to have signed this new sales and marketing agreement with Cura. We believe Mucotrol will demonstrate strong commercial interest in the relief of side effects of those patients undergoing chemotherapy treatments.”